| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| July 23rd, 2004 | 26 | Yes |
Popular Name: Camptothecin Camptothecin
Find On: PubMed — Wikipedia — Google
CAS Numbers: 31456-25-4 , 7689-03-4 , [7689-03-4]
(+)-camptothecine; (s)-camptothecine; CPD-11776; camptothecin; camptothecine; d-camptothecine
(4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
(S)-4-Ethyl-4-hydroxy-1H-pyrano[3`,4`:6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione
21,22-Secocamptothecin-21-oic acid lactone
4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione
4-ETHYL-4-HYDROXY-3,4,12,14-TETRAHYDRO-1H-PYRANO[3'4':6,7]INDOLIZINO[1,2-B]QUINOLINE-3,14-DIONE
7689-03-4; C01897; Camptothecin
7689-03-4; Camptothecine (S,+); Prestwick_102
Camptothecine, Antibiotic for Culture Media Use Only
Ethyl-4-hydroxy-1H-pyrano[3_,4_:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 2.03 | 6.76 | -12.81 | 1 | 6 | 0 | 81 | 348.358 | 1 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| biological_source | Alkaloid from Camptotheca acuminata, Mappia foetida, Ervatamia heyneana and Ophiorrhiza mungos (Nyssaceae, Rubiaceae, Apocynaceae) | ZereneX Building Blocks |
| MP | 255-257° (dec) | Matrix Scientific |
| Mp [°C] | 260 | Acros Organics |
| ALOGPS_SOLUBILITY | 5.11e-01 g/l | DrugBank-experimental |
| Purity | 95+% | Matrix Scientific |
| Purity | >98% | Fluorochem |
| Notes | A potent antitumor antibiotic | Apollo Scientific Bioactives |
| UniProt Database Links | ABCG2_HUMAN; ANM7_CRILO; ANM7_HUMAN; CENPS_BOVIN; CENPS_CHICK; CENPS_HUMAN; CENPS_MOUSE; CPT1A_HORSE; CPT1A_HUMAN; CPT1A_MOUSE; CPT1A_RAT; CPT1B_BOVIN; CPT1B_HUMAN; CPT1B_MOUSE; CPT1B_PIG; CPT1B_RAT; CPT1C_HUMAN; CPT1C_MOUSE; CPT1C_RAT; CPT2_BOVIN; CPT2_D | ChEBI |
| Indications | anticancer | KeyOrganics Bioactives |
| Therapy | antineoplastic | SMDC MicroSource |
| biological_use | Cytostatic | IBScreen Bioactives |
| H phrase | H301: Toxic if swallowed | Acros Organics |
| mechanism | Inhibits the DNA enzyme topoisomerase | IBScreen Bioactives |
| Warnings | IRRITANT | Matrix Scientific |
| P phrase | P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician | Acros Organics |
| R phrase | R25: Toxic if swallowed. | Acros Organics |
| S phrase | S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. | Acros Organics |
| S phrase | S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.; S45: In case of accident or if you feel unwell, seek medical advice immediat | Acros Organics |
| biological_use | Severe side effects and rapid hydrol. at physiological pH have inhibited widespread clinical use | IBScreen Bioactives |
| biological_use | Shows anti-HIV and antiprotozoal activity | IBScreen Bioactives |
| biological_use | Shows plant growth regulatory and insect chemosterilant props. | IBScreen Bioactives |
| biological_use | Shows potent antineoplastic activity in exp. animals | IBScreen Bioactives IBScreen Bioactives |
| Hazard | T: Toxic | Acros Organics |
| Target | Topoisomerase | Selleck Chemicals |
| biological_use | Used clinically in China against gastrointestinal tumours | IBScreen Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| TOP1-1-E | DNA Topoisomerase 1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 1600 | 0.31 | Binding ≤ 10μM |
| TOP1-1-E | DNA Topoisomerase 1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 9000 | 0.27 | Binding ≤ 10μM |
| CHK1-1-E | Serine/threonine-protein Kinase Chk1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.47 | Functional ≤ 10μM |
| SSR1-1-E | Somatostatin Receptor 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.47 | Functional ≤ 10μM |
| SSR2-1-E | Somatostatin Receptor 2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.47 | Functional ≤ 10μM |
| SSR3-1-E | Somatostatin Receptor 3 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.47 | Functional ≤ 10μM |
| SSR4-1-E | Somatostatin Receptor 4 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.47 | Functional ≤ 10μM |
| SSR5-1-E | Somatostatin Receptor 5 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2 | 0.47 | Functional ≤ 10μM |
| TOP1-1-E | DNA Topoisomerase I (cluster #1 Of 1), Eukaryotic | Eukaryotes | 33 | 0.40 | Functional ≤ 10μM |
| TOP2A-1-E | DNA Topoisomerase II Alpha (cluster #1 Of 1), Eukaryotic | Eukaryotes | 33 | 0.40 | Functional ≤ 10μM |
| TOP2B-1-E | DNA Topoisomerase II Beta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 33 | 0.40 | Functional ≤ 10μM |
| Z100501-1-O | Lu1 (Lung Carcinoma Cells) (cluster #1 Of 2), Other | Other | 29 | 0.41 | Functional ≤ 10μM |
| Z100733-1-O | CT26 (Colon Carcinoma Cells) (cluster #1 Of 1), Other | Other | 34 | 0.40 | Functional ≤ 10μM |
| Z100752-1-O | Renca (Renal Carcinoma Cells) (cluster #1 Of 1), Other | Other | 304 | 0.35 | Functional ≤ 10μM |
| Z103205-1-O | A431 (cluster #1 Of 4), Other | Other | 11 | 0.43 | Functional ≤ 10μM |
| Z103408-1-O | SW626 (cluster #1 Of 2), Other | Other | 29 | 0.41 | Functional ≤ 10μM |
| Z103413-1-O | SW948 (cluster #1 Of 1), Other | Other | 160 | 0.37 | Functional ≤ 10μM |
| Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 794 | 0.33 | Functional ≤ 10μM |
| Z80012-1-O | A 172 (Glioblastoma Cells) (cluster #1 Of 1), Other | Other | 29 | 0.41 | Functional ≤ 10μM |
| Z80012-1-O | A 172 (Glioblastoma Cells) (cluster #1 Of 1), Other | Other | 140 | 0.37 | Functional ≤ 10μM |
| Z80019-1-O | A-427 (Lung Carcinoma Cells) (cluster #1 Of 4), Other | Other | 24 | 0.41 | Functional ≤ 10μM |
| Z80026-1-O | AGS (Gastric Adenocarcinoma Cells) (cluster #1 Of 2), Other | Other | 20 | 0.41 | Functional ≤ 10μM |
| Z80054-1-O | Caco-2 (Colon Adenocarcinoma Cells) (cluster #1 Of 4), Other | Other | 9550 | 0.27 | Functional ≤ 10μM |
| Z80056-1-O | CAKI-2 (Renal Carcinoma Cells) (cluster #1 Of 1), Other | Other | 3960 | 0.29 | Functional ≤ 10μM |
| Z80064-1-O | CCRF-CEM (T-cell Leukemia) (cluster #1 Of 9), Other | Other | 5300 | 0.28 | Functional ≤ 10μM |
| Z80068-3-O | CCRF-SB (Lymphoblastic Leukemia Cells) (cluster #3 Of 5), Other | Other | 3 | 0.46 | Functional ≤ 10μM |
| Z80099-1-O | COLO 205 (Colon Adenocarcinoma Cells) (cluster #1 Of 3), Other | Other | 5 | 0.45 | Functional ≤ 10μM |
| Z80115-1-O | DC3F (cluster #1 Of 1), Other | Other | 6 | 0.44 | Functional ≤ 10μM |
| Z80120-1-O | DLD-1 (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 102 | 0.38 | Functional ≤ 10μM |
| Z80120-1-O | DLD-1 (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 210 | 0.36 | Functional ≤ 10μM |
| Z80125-1-O | DU-145 (Prostate Carcinoma) (cluster #1 Of 9), Other | Other | 940 | 0.32 | Functional ≤ 10μM |
| Z80145-3-O | H69 (cluster #3 Of 4), Other | Other | 1 | 0.48 | Functional ≤ 10μM |
| Z80152-1-O | HCT-8 (Ileocecal Adenocarcinoma) (cluster #1 Of 2), Other | Other | 7 | 0.44 | Functional ≤ 10μM |
| Z80156-2-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #2 Of 12), Other | Other | 89 | 0.38 | Functional ≤ 10μM |
| Z80164-1-O | HT-1080 (Fibrosarcoma Cells) (cluster #1 Of 6), Other | Other | 80 | 0.38 | Functional ≤ 10μM |
| Z80166-1-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #1 Of 12), Other | Other | 90 | 0.38 | Functional ≤ 10μM |
| Z80186-1-O | K562 (Erythroleukemia Cells) (cluster #1 Of 11), Other | Other | 80 | 0.38 | Functional ≤ 10μM |
| Z80188-1-O | KB 3-1 (Cervical Epithelial Carcinoma Cells) (cluster #1 Of 2), Other | Other | 20 | 0.41 | Functional ≤ 10μM |
| Z80193-2-O | L1210 (Lymphocytic Leukemia Cells) (cluster #2 Of 12), Other | Other | 35 | 0.40 | Functional ≤ 10μM |
| Z80193-2-O | L1210 (Lymphocytic Leukemia Cells) (cluster #2 Of 12), Other | Other | 60 | 0.39 | Functional ≤ 10μM |
| Z80211-1-O | LoVo (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 3100 | 0.30 | Functional ≤ 10μM |
| Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 7420 | 0.28 | Functional ≤ 10μM |
| Z80269-1-O | MKN-45 (Gastric Adenocarcinoma Cells) (cluster #1 Of 3), Other | Other | 17 | 0.42 | Functional ≤ 10μM |
| Z80295-2-O | MT4 (Lymphocytes) (cluster #2 Of 8), Other | Other | 4 | 0.45 | Functional ≤ 10μM |
| Z80316-1-O | NCI-H128 (cluster #1 Of 1), Other | Other | 18 | 0.42 | Functional ≤ 10μM |
| Z80362-1-O | P388 (Lymphoma Cells) (cluster #1 Of 8), Other | Other | 9 | 0.43 | Functional ≤ 10μM |
| Z80372-1-O | P388CPT5 (cluster #1 Of 1), Other | Other | 2800 | 0.30 | Functional ≤ 10μM |
| Z80390-1-O | PC-3 (Prostate Carcinoma Cells) (cluster #1 Of 10), Other | Other | 57 | 0.39 | Functional ≤ 10μM |
| Z80414-1-O | Raji (B-lymphoblastic Cells) (cluster #1 Of 3), Other | Other | 1000 | 0.32 | Functional ≤ 10μM |
| Z80466-1-O | SF268 (cluster #1 Of 4), Other | Other | 40 | 0.40 | Functional ≤ 10μM |
| Z80475-1-O | SK-BR-3 (Breast Adenocarcinoma) (cluster #1 Of 3), Other | Other | 20 | 0.41 | Functional ≤ 10μM |
| Z80482-2-O | SK-MEL-2 (Melanoma Cells) (cluster #2 Of 4), Other | Other | 7860 | 0.27 | Functional ≤ 10μM |
| Z80485-1-O | SK-MEL-28 (Melanoma Cells) (cluster #1 Of 6), Other | Other | 40 | 0.40 | Functional ≤ 10μM |
| Z80493-1-O | SK-OV-3 (Ovarian Carcinoma Cells) (cluster #1 Of 6), Other | Other | 51 | 0.39 | Functional ≤ 10μM |
| Z80495-1-O | SK-VLB (cluster #1 Of 1), Other | Other | 53 | 0.39 | Functional ≤ 10μM |
| Z80532-1-O | T-24 (Bladder Carcinoma Cells) (cluster #1 Of 6), Other | Other | 88 | 0.38 | Functional ≤ 10μM |
| Z80548-1-O | THP-1 (Acute Monocytic Leukemia Cells) (cluster #1 Of 5), Other | Other | 600 | 0.34 | Functional ≤ 10μM |
| Z80623-1-O | Panel (56 Tumour Cell Lines) (cluster #1 Of 1), Other | Other | 40 | 0.40 | Functional ≤ 10μM |
| Z80647-1-O | 833K Cell Line (cluster #1 Of 1), Other | Other | 10 | 0.43 | Functional ≤ 10μM |
| Z80682-1-O | A549 (Lung Carcinoma Cells) (cluster #1 Of 11), Other | Other | 91 | 0.38 | Functional ≤ 10μM |
| Z80697-1-O | Bel-7402 (Hepatoma Cells) (cluster #1 Of 3), Other | Other | 7 | 0.44 | Functional ≤ 10μM |
| Z80712-2-O | T47D (Breast Carcinoma Cells) (cluster #2 Of 7), Other | Other | 207 | 0.36 | Functional ≤ 10μM |
| Z80751-1-O | Caov-3 Cell Line (cluster #1 Of 1), Other | Other | 30 | 0.41 | Functional ≤ 10μM |
| Z80751-1-O | Caov-3 Cell Line (cluster #1 Of 1), Other | Other | 32 | 0.40 | Functional ≤ 10μM |
| Z80784-1-O | Col2 (Colon Carcinoma Cells) (cluster #1 Of 2), Other | Other | 45 | 0.40 | Functional ≤ 10μM |
| Z80799-1-O | RPMI 8402 (Pre-T-lymphoblastoid Cells) (cluster #1 Of 1), Other | Other | 6 | 0.44 | Functional ≤ 10μM |
| Z80874-1-O | CEM (T-cell Leukemia) (cluster #1 Of 7), Other | Other | 1 | 0.48 | Functional ≤ 10μM |
| Z80898-1-O | NCI-H928 (cluster #1 Of 1), Other | Other | 8 | 0.44 | Functional ≤ 10μM |
| Z80928-1-O | HCT-116 (Colon Carcinoma Cells) (cluster #1 Of 9), Other | Other | 9 | 0.43 | Functional ≤ 10μM |
| Z80930-1-O | HEC-1B Cell Line (cluster #1 Of 1), Other | Other | 60 | 0.39 | Functional ≤ 10μM |
| Z80930-1-O | HEC-1B Cell Line (cluster #1 Of 1), Other | Other | 8640 | 0.27 | Functional ≤ 10μM |
| Z81017-1-O | WiDr (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 17 | 0.42 | Functional ≤ 10μM |
| Z81020-7-O | HepG2 (Hepatoblastoma Cells) (cluster #7 Of 8), Other | Other | 60 | 0.39 | Functional ≤ 10μM |
| Z81024-1-O | NCI-H460 (Non-small Cell Lung Carcinoma) (cluster #1 Of 8), Other | Other | 330 | 0.35 | Functional ≤ 10μM |
| Z81034-1-O | A2780 (Ovarian Carcinoma Cells) (cluster #1 Of 10), Other | Other | 7 | 0.44 | Functional ≤ 10μM |
| Z81054-1-O | SF-268 (Glioblastoma Cells) (cluster #1 Of 3), Other | Other | 59 | 0.39 | Functional ≤ 10μM |
| Z81072-1-O | Jurkat (Acute Leukemic T-cells) (cluster #1 Of 10), Other | Other | 6 | 0.44 | Functional ≤ 10μM |
| Z81080-1-O | KATO-III Cell Line (cluster #1 Of 1), Other | Other | 448 | 0.34 | Functional ≤ 10μM |
| Z81080-1-O | KATO-III Cell Line (cluster #1 Of 1), Other | Other | 1170 | 0.32 | Functional ≤ 10μM |
| Z81084-1-O | KB VCR R (cluster #1 Of 1), Other | Other | 9 | 0.43 | Functional ≤ 10μM |
| Z81115-2-O | KB (Squamous Cell Carcinoma) (cluster #2 Of 6), Other | Other | 9 | 0.43 | Functional ≤ 10μM |
| Z81134-1-O | L2987 (Lung Adenocarcinoma Cells) (cluster #1 Of 1), Other | Other | 400 | 0.34 | Functional ≤ 10μM |
| Z81160-1-O | Lewis Lung Carcinoma Cell Line (cluster #1 Of 1), Other | Other | 33 | 0.40 | Functional ≤ 10μM |
| Z81164-1-O | LL Cell Line (cluster #1 Of 2), Other | Other | 33 | 0.40 | Functional ≤ 10μM |
| Z81170-1-O | LNCaP (Prostate Carcinoma) (cluster #1 Of 5), Other | Other | 86 | 0.38 | Functional ≤ 10μM |
| Z81184-1-O | LOX IMVI (Melanoma Cells) (cluster #1 Of 5), Other | Other | 48 | 0.39 | Functional ≤ 10μM |
| Z81245-1-O | MDA-MB-435 (Breast Carcinoma Cells) (cluster #1 Of 6), Other | Other | 710 | 0.33 | Functional ≤ 10μM |
| Z81247-1-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #1 Of 9), Other | Other | 940 | 0.32 | Functional ≤ 10μM |
| Z81252-3-O | MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #3 Of 11), Other | Other | 970 | 0.32 | Functional ≤ 10μM |
| Z81331-1-O | SW-620 (Colon Adenocarcinoma Cells) (cluster #1 Of 6), Other | Other | 2 | 0.47 | Functional ≤ 10μM |
| Z81335-1-O | HCT-15 (Colon Adenocarcinoma Cells) (cluster #1 Of 5), Other | Other | 83 | 0.38 | Functional ≤ 10μM |
| Z80291-2-O | MRC5 (Embryonic Lung Fibroblast Cells) (cluster #2 Of 3), Other | Other | 890 | 0.33 | ADME/T ≤ 10μM |
| Z81247-1-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #1 Of 3), Other | Other | 500 | 0.34 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| TOP1_HUMAN | P11387 | DNA Topoisomerase I, Human | 300 | 0.35 | Binding ≤ 1μM |
| TOP1_HUMAN | P11387 | DNA Topoisomerase I, Human | 1400 | 0.32 | Binding ≤ 10μM |
| Z80647 | Z80647 | 833K Cell Line | 10 | 0.43 | Functional ≤ 10μM |
| Z80012 | Z80012 | A 172 (Glioblastoma Cells) | 29 | 0.41 | Functional ≤ 10μM |
| Z80019 | Z80019 | A-427 (Lung Carcinoma Cells) | 24 | 0.41 | Functional ≤ 10μM |
| Z81034 | Z81034 | A2780 (Ovarian Carcinoma Cells) | 200 | 0.36 | Functional ≤ 10μM |
| Z103205 | Z103205 | A431 | 11 | 0.43 | Functional ≤ 10μM |
| Z80682 | Z80682 | A549 (Lung Carcinoma Cells) | 10 | 0.43 | Functional ≤ 10μM |
| Z80026 | Z80026 | AGS (Gastric Adenocarcinoma Cells) | 20 | 0.41 | Functional ≤ 10μM |
| Z80697 | Z80697 | Bel-7402 (Hepatoma Cells) | 7 | 0.44 | Functional ≤ 10μM |
| Z80054 | Z80054 | Caco-2 (Colon Adenocarcinoma Cells) | 9550 | 0.27 | Functional ≤ 10μM |
| Z80056 | Z80056 | CAKI-2 (Renal Carcinoma Cells) | 3960 | 0.29 | Functional ≤ 10μM |
| Z80751 | Z80751 | Caov-3 Cell Line | 32 | 0.40 | Functional ≤ 10μM |
| Z80064 | Z80064 | CCRF-CEM (T-cell Leukemia) | 3 | 0.46 | Functional ≤ 10μM |
| Z80068 | Z80068 | CCRF-SB (Lymphoblastic Leukemia Cells) | 3 | 0.46 | Functional ≤ 10μM |
| Z80874 | Z80874 | CEM (T-cell Leukemia) | 0.84 | 0.49 | Functional ≤ 10μM |
| Z80784 | Z80784 | Col2 (Colon Carcinoma Cells) | 45 | 0.40 | Functional ≤ 10μM |
| Z80099 | Z80099 | COLO 205 (Colon Adenocarcinoma Cells) | 5.4 | 0.45 | Functional ≤ 10μM |
| Z100733 | Z100733 | CT26 (Colon Carcinoma Cells) | 34 | 0.40 | Functional ≤ 10μM |
| Z80115 | Z80115 | DC3F | 6 | 0.44 | Functional ≤ 10μM |
| Z80120 | Z80120 | DLD-1 (Colon Adenocarcinoma Cells) | 102 | 0.38 | Functional ≤ 10μM |
| TOP1_HUMAN | P11387 | DNA Topoisomerase I, Human | 5.6 | 0.44 | Functional ≤ 10μM |
| TOP1_MOUSE | Q04750 | DNA Topoisomerase I, Mouse | 33 | 0.40 | Functional ≤ 10μM |
| TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 5.6 | 0.44 | Functional ≤ 10μM |
| TOP2A_MOUSE | Q01320 | DNA Topoisomerase II Alpha, Mouse | 33 | 0.40 | Functional ≤ 10μM |
| TOP2B_MOUSE | Q64511 | DNA Topoisomerase II Beta, Mouse | 33 | 0.40 | Functional ≤ 10μM |
| TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 5.6 | 0.44 | Functional ≤ 10μM |
| Z80125 | Z80125 | DU-145 (Prostate Carcinoma) | 10 | 0.43 | Functional ≤ 10μM |
| Z80145 | Z80145 | H69 | 1 | 0.48 | Functional ≤ 10μM |
| Z80928 | Z80928 | HCT-116 (Colon Carcinoma Cells) | 1000 | 0.32 | Functional ≤ 10μM |
| Z81335 | Z81335 | HCT-15 (Colon Adenocarcinoma Cells) | 166 | 0.37 | Functional ≤ 10μM |
| Z80152 | Z80152 | HCT-8 (Ileocecal Adenocarcinoma) | 7 | 0.44 | Functional ≤ 10μM |
| Z80930 | Z80930 | HEC-1B Cell Line | 60 | 0.39 | Functional ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 1080 | 0.32 | Functional ≤ 10μM |
| Z81020 | Z81020 | HepG2 (Hepatoblastoma Cells) | 130 | 0.37 | Functional ≤ 10μM |
| Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 100 | 0.38 | Functional ≤ 10μM |
| Z80164 | Z80164 | HT-1080 (Fibrosarcoma Cells) | 80 | 0.38 | Functional ≤ 10μM |
| Z80166 | Z80166 | HT-29 (Colon Adenocarcinoma Cells) | 10000 | 0.27 | Functional ≤ 10μM |
| Z81072 | Z81072 | Jurkat (Acute Leukemic T-cells) | 1.4 | 0.48 | Functional ≤ 10μM |
| Z80186 | Z80186 | K562 (Erythroleukemia Cells) | 1400 | 0.32 | Functional ≤ 10μM |
| Z81080 | Z81080 | KATO-III Cell Line | 448 | 0.34 | Functional ≤ 10μM |
| Z81115 | Z81115 | KB (Squamous Cell Carcinoma) | 1040 | 0.32 | Functional ≤ 10μM |
| Z80188 | Z80188 | KB 3-1 (Cervical Epithelial Carcinoma Cells) | 10 | 0.43 | Functional ≤ 10μM |
| Z81084 | Z81084 | KB VCR R | 9 | 0.43 | Functional ≤ 10μM |
| Z80193 | Z80193 | L1210 (Lymphocytic Leukemia Cells) | 35 | 0.40 | Functional ≤ 10μM |
| Z81134 | Z81134 | L2987 (Lung Adenocarcinoma Cells) | 400 | 0.34 | Functional ≤ 10μM |
| Z81160 | Z81160 | Lewis Lung Carcinoma Cell Line | 33 | 0.40 | Functional ≤ 10μM |
| Z81164 | Z81164 | LL Cell Line | 33 | 0.40 | Functional ≤ 10μM |
| Z81170 | Z81170 | LNCaP (Prostate Carcinoma) | 86.1 | 0.38 | Functional ≤ 10μM |
| Z80211 | Z80211 | LoVo (Colon Adenocarcinoma Cells) | 3100 | 0.30 | Functional ≤ 10μM |
| Z81184 | Z81184 | LOX IMVI (Melanoma Cells) | 48 | 0.39 | Functional ≤ 10μM |
| Z100501 | Z100501 | Lu1 (Lung Carcinoma Cells) | 28.7 | 0.41 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1.6 | 0.47 | Functional ≤ 10μM |
| Z81252 | Z81252 | MDA-MB-231 (Breast Adenocarcinoma Cells) | 1100 | 0.32 | Functional ≤ 10μM |
| Z81245 | Z81245 | MDA-MB-435 (Breast Carcinoma Cells) | 15 | 0.42 | Functional ≤ 10μM |
| Z80269 | Z80269 | MKN-45 (Gastric Adenocarcinoma Cells) | 17 | 0.42 | Functional ≤ 10μM |
| Z80295 | Z80295 | MT4 (Lymphocytes) | 4 | 0.45 | Functional ≤ 10μM |
| Z80316 | Z80316 | NCI-H128 | 18 | 0.42 | Functional ≤ 10μM |
| Z81024 | Z81024 | NCI-H460 (Non-small Cell Lung Carcinoma) | 30 | 0.41 | Functional ≤ 10μM |
| Z80898 | Z80898 | NCI-H928 | 7.8 | 0.44 | Functional ≤ 10μM |
| Z80362 | Z80362 | P388 (Lymphoma Cells) | 0.1 | 0.54 | Functional ≤ 10μM |
| Z80372 | Z80372 | P388CPT5 | 2800 | 0.30 | Functional ≤ 10μM |
| Z80623 | Z80623 | Panel (56 Tumour Cell Lines) | 40 | 0.40 | Functional ≤ 10μM |
| Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 12 | 0.43 | Functional ≤ 10μM |
| Z50425 | Z50425 | Plasmodium Falciparum | 0.56 | 0.50 | Functional ≤ 10μM |
| Z80414 | Z80414 | Raji (B-lymphoblastic Cells) | 1000 | 0.32 | Functional ≤ 10μM |
| Z100752 | Z100752 | Renca (Renal Carcinoma Cells) | 304 | 0.35 | Functional ≤ 10μM |
| Z80799 | Z80799 | RPMI 8402 (Pre-T-lymphoblastoid Cells) | 5 | 0.45 | Functional ≤ 10μM |
| CHK1_HUMAN | O14757 | Serine/threonine-protein Kinase Chk1, Human | 2.1 | 0.47 | Functional ≤ 10μM |
| Z81054 | Z81054 | SF-268 (Glioblastoma Cells) | 59 | 0.39 | Functional ≤ 10μM |
| Z80466 | Z80466 | SF268 | 190 | 0.36 | Functional ≤ 10μM |
| Z80475 | Z80475 | SK-BR-3 (Breast Adenocarcinoma) | 20 | 0.41 | Functional ≤ 10μM |
| Z80482 | Z80482 | SK-MEL-2 (Melanoma Cells) | 165 | 0.37 | Functional ≤ 10μM |
| Z80485 | Z80485 | SK-MEL-28 (Melanoma Cells) | 40 | 0.40 | Functional ≤ 10μM |
| Z80493 | Z80493 | SK-OV-3 (Ovarian Carcinoma Cells) | 14 | 0.42 | Functional ≤ 10μM |
| Z80495 | Z80495 | SK-VLB | 41 | 0.40 | Functional ≤ 10μM |
| SSR1_HUMAN | P30872 | Somatostatin Receptor 1, Human | 2.21 | 0.47 | Functional ≤ 10μM |
| SSR2_HUMAN | P30874 | Somatostatin Receptor 2, Human | 2.21 | 0.47 | Functional ≤ 10μM |
| SSR3_HUMAN | P32745 | Somatostatin Receptor 3, Human | 2.21 | 0.47 | Functional ≤ 10μM |
| SSR4_HUMAN | P31391 | Somatostatin Receptor 4, Human | 2.21 | 0.47 | Functional ≤ 10μM |
| SSR5_HUMAN | P35346 | Somatostatin Receptor 5, Human | 2.21 | 0.47 | Functional ≤ 10μM |
| Z81331 | Z81331 | SW-620 (Colon Adenocarcinoma Cells) | 0.15 | 0.53 | Functional ≤ 10μM |
| Z103408 | Z103408 | SW626 | 28.7 | 0.41 | Functional ≤ 10μM |
| Z103413 | Z103413 | SW948 | 160 | 0.37 | Functional ≤ 10μM |
| Z80532 | Z80532 | T-24 (Bladder Carcinoma Cells) | 88 | 0.38 | Functional ≤ 10μM |
| Z80712 | Z80712 | T47D (Breast Carcinoma Cells) | 207 | 0.36 | Functional ≤ 10μM |
| Z80548 | Z80548 | THP-1 (Acute Monocytic Leukemia Cells) | 160 | 0.37 | Functional ≤ 10μM |
| Z81017 | Z81017 | WiDr (Colon Adenocarcinoma Cells) | 17 | 0.42 | Functional ≤ 10μM |
| Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 500 | 0.34 | ADME/T ≤ 10μM |
| Z80291 | Z80291 | MRC5 (Embryonic Lung Fibroblast Cells) | 890 | 0.33 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Activation of ATR in response to replication stress | |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |
| G alpha (i) signalling events | |
| G0 and Early G1 | |
| G2/M DNA damage checkpoint | |
| Peptide ligand-binding receptors | |
| Signaling by SCF-KIT | |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A |
